Just Answers - Finance

When a person in financial difficulties wants to avoid bankruptcy, they generally have two options. They can take either, an informal debt management program, or the formal
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
b> IVA route. Here is a comparison of the two choices:

The informal route option will either be:

A debtor talking to their creditors directly, explaining to them that they cannot
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in
continue with their monthly repayments at the agreed level, and asking for a reduction of repayments for themselves. A debtor who approaches creditors directly will save on the management fees of a
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

commercial debt management company, but will have to deal with the problem at first hand. This is never an easy task, and is made even more difficult when a debtor has multiple creditors.
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
or

A debtor employing the services of a debt management company, who in turn will contact the creditors on behalf of the debtor and negotiate lower monthly repayments for them. However, a
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro
debtor that chooses to use the services of a commercial debt management company will face the cost of management fees each month, which will actually reduce how much can, in turn, be paid to the cr
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
editors.

Both of these informal agreements have a role to play in the debt solution market place, and deciding on which is the most suitable option will be down to the individual circumst
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
nces of each case.

Other issues to consider with an informal debt management agreement are:

The debtor will be expected to make a full repayment of the debt.

The creditors may
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
not freeze the interest on the outstanding debt.
The creditors can still take legal action for the recovery of the debt.

The debtor's credit file will be effected by default noti
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
ces once the debtor enters the informal arrangement.

The formal route will be an IVA.

An Individual Voluntary Arrangement gives a debtor, with debts over ?15,000, a real al
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
ernative to both informal choices above, and formal bankruptcy.

The IVA is, in essence, a legally binding contractual agreement between the debtor and the creditors. It is lodge in court and held o
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a
n the public register of IVAs within the Dept of Trade and Industry (D.T.i.).

The general terms of the IVA proposal give great benefits to the debtor.

Here are a few of the main points:

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod
>IVA monthly repayments are set at a predetermined affordable amount.

The debtor's repayments will last for a fixed term, normally 5 years.

An IVA protects the debtor's home from
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
creditors

The creditors cannot contact the debtor to request changes to the terms of the IVA.

The creditors cannot take legal action, with regards to the outstanding debts.
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

If the debt is not repaid in full after the IVA has finished, the creditors must write-off the balance.

The creditors are obliged to freeze the interest on the debts.

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
>The IVA offers a debt solution to certain professionals that are unable to petition for their own bankruptcy.

There are a few negative points to bear in mind though:

A debtor
ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust
must maintain the repayments of the IVA, as the creditors can petition for bankruptcy if there are continuous missed repayments

The debtor will have their finances reviewed annually.

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
A debtor is barred from obtaining further credit whilst in their IVA.

So, in short, the IVA bridges the gap between bankruptcy and debt management. It gives protection to the debtor a
.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
nd allows them to offer realistic repayment terms to the creditors, and it gives the creditors a better financial alternative to bankruptcy.

Not all debtors will qualify for an IVA.

There are seve
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip
ral restrictions that determine whether or not a debtor's circumstances are suitable for the IVA to be a viable solution.

But when the circumstances are right, the IVA wins by a country mile

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

Tags

Links

Just Answers - IVA or Debt Management Program?

Related Articles: